Tinnitus cure updates
AC102 (AudioCure Pharma): In preclinical (animal) models of noise-induced damage, a single dose almost completely reversed tinnitus and restored connections between inner-ear hair cells and the auditory nerve. It's now in Phase 2 clinical trials for sudden sensorineural hearing loss (often linked to tinnitus), with tinnitus effects also being studied. Human results are pending (expected updates around 2026), but it's one of the most exciting regenerative candidates.